Press Releases & Announcements

REPRIEVE TRIAL CARDIOVASCULAR DISEASE RISK AND PREVENTION IN INFLAMMATION: THE REPRIEVE TRIAL IN HIV

Jan 11, 2023

A MESSAGE FROM LEADERSHIP - CLUB Q STATEMENT OF SOLIDARITY

Nov 23, 2022

ACTG PRESENTS DATA SHOWING SUCCESS OF HEPATITIS B VACCINE AMONG PEOPLE LIVING WITH HIV AT IDWEEK 2022

Oct 20, 2022

ACTG MAKES THREE COVID-19-FOCUSED PRESENTATIONS AT IDWEEK 2022

Oct 20, 2022

ACTG ANNOUNCES RESULTS FROM INVESTIGATIONAL INHALED COVID-19 TREATMENT IN ACTIV-2 PHASE 2 STUDY

Oct 04, 2022

IDSA MEDIA BRIEFING ON MONKEYPOX TREATMENT TRIALS

Oct 03, 2022

ACTG ANNOUNCES LAUNCH OF TRIAL EVALUATING MONKEYPOX TREATMENT

Sep 09, 2022

SOLICITATION FOR ACTG SCIENCE COMMITTEE MEMBERSHIP POSITIONS DUE SEPTEMBER 21ST

Aug 26, 2022

UPCOMING MONKEYPOX STUDY

Aug 22, 2022

ACTG ANNOUNCES LAUNCH OF ACTIV-2D, A GLOBAL PHASE 3 TRIAL OF THE NOVEL INVESTIGATIONAL COVID-19 ORAL ANTIVIRAL AGENT S‑217622

Aug 15, 2022

ACTG ANNOUNCES PUBLICATION OF #ACTIV-2 STUDY IN CELL REPORTS MEDICINE DEMONSTRATING RAPID CLEARANCE OF CULTURABLE SARS-COV-2 FOLLOWING MONOCLONAL ANTIBODY TREATMENT

Jul 27, 2022

ACTG LAUNCHES A5383, CLINICAL TRIAL EVALUATING POTENTIAL IMMUNOLOGIC BENEFITS OF TREATING ASYMPTOMATIC CMV IN PEOPLE LIVING WITH HIV

Apr 22, 2022